Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05892744
PHASE4

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Sponsor: University of Texas at Austin

View on ClinicalTrials.gov

Summary

The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

Official title: Establishing Multimodal Brain Biomarkers Using Data-driven Analytics for Treatment Selection in Depression

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2023-09-30

Completion Date

2027-07-15

Last Updated

2025-01-09

Healthy Volunteers

No

Interventions

DRUG

Sertraline

50-200mg/day

Locations (1)

Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600

Austin, Texas, United States